South Africa has secured 20 million doses of the Pfizer/BioNTech coronavirus vaccine, the health minister told a Sunday newspaper.
Africa’s worst virus-hit country has yet to begin vaccinating its population against COVID-19, stirring criticism over slow procurement and lack of strategy.
A first shipment of AstraZeneca/Oxford jabs produced in India is due to arrive on Monday, with injections expected to start two weeks later.
Health Minister Zweli Mkhize told The Sunday Times that 20 million additional vaccines had been ordered from US drugmaker Pfizer.
“These vaccines are secured and awaiting manufacturers to submit final agreements with details of delivery dates and exact amounts,” said Mkhize.
The health ministry did not respond to several AFP requests for comment.
The new Pfizer order will complement 12 million vaccine doses from the WHO-backed Covax facility, nine million Johnson & Johnson shots and 1.5 million AstraZeneca/Oxford vaccines—pushing the total supply secured so far to over 40 million.
South Africa aims to vaccinate 67 percent of the population, or 40 million people, by the end of the year.
Some vaccines will be provided by Covax and the African Union, while others will be directly purchased from suppliers.
“We are reasonably comfortable that what we have paid for, signed for and are negotiating for will cover the numbers that we are looking to vaccinate,” Mkhize assured.
The minister added that storage of the Pfizer/BioNTech vaccine, which needs to be kept at -70 degrees Celsius, would not be an issue.
“We have some capacity, mostly in academic institutions. There are now companies coming forward with storage and transit solutions,” he said.
South Africa’s coronavirus outbreak has been accelerated by a new variant thought to be more contagious than earlier forms and relatively more resistant to existing vaccines.
To date the country has recorded more than 1.4 million infections and almost 45,000 deaths.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2021 AFP
S.Africa orders 20 mln Pfizer vaccines: report (2021, January 31)
retrieved 31 January 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022